SCHEMBL4424986

SCHEMBL4424986

CC(C)(C)OC(=O)N1CC2C(CNc3ccc(N4CCOCC4)c(F)c3)C2C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.44
HTT P42858 1/20 0.44
GAA P10253 3/20 0.44
ALOX15 P16050 2/20 0.44
MAPK1 P28482 1/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 2/20 0.43
LDHA P00338 1/20 0.43
LDHB P07195 1/20 0.43
MAOB P27338 2/20 0.43
LMNA P02545 2/20 0.43
MAOA P21397 1/20 0.43
PTGS1 P23219 1/20 0.43
CALML3 P27482 1/20 0.43
SDHA P31040 1/20 0.43
TGFBR1 P36897 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPT P10636 1/20 0.41
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5188060 0.86 TGFBR1 (0.56) USP30TGFBR1ALDH2
SCHEMBL4415020 0.84 HTT (0.48) USP30L3MBTL1HTTGAAALOX15
SCHEMBL4424781 0.83 USP30 (0.44) USP30L3MBTL1HTTGAAALOX15
SCHEMBL4421230 0.82 MAOA (0.44) USP30L3MBTL1HTTGAAALOX15
SCHEMBL4421406 0.81 NPC1 (0.47) USP30L3MBTL1HTTGAAALOX15
SCHEMBL4417990 0.80 HTT (0.44) USP30L3MBTL1HTTALOX15MAPK1
SCHEMBL4415737 0.78 P2RX3 (0.39) USP30L3MBTL1HTTGAAALOX15
SCHEMBL4414369 0.78 L3MBTL1 (0.47) USP30L3MBTL1HTTGAANPC1
Trifluoroacetic Acid SCHEMBL4421351 0.77 NPC1 (0.47) L3MBTL1HTTGAAALOX15MAPK1
SCHEMBL4420889 0.77 MAOB (0.45) USP30L3MBTL1HTTGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 USP30 4095/4885L3MBTL1 1416/4885HTT 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.